Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Neuronetics (STIM) PT Lowered to $3 at Canaccord Genuity
August 13, 2024 6:23 AM EDTCanaccord Genuity analyst William Plovanic lowered the price target on Neuronetics (NASDAQ: STIM) to $3.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "Bottom line: STIMs Q2/24 missed estimates with $16.5M of revenue, driven by low treatment session revenue as customers delayed refilling inventory due to continued prior authorization and reimbursement headwinds from Change Healthcares cybersecurity breach impacting STIMs customer base. That said, STIM reiterated its FY24 revenue guidance of $78M-$80M, displaying confidence in the... More
